Recent blog posts
C3 glomerulopathy Indication Strategy Report 2026: C3, Trials and Deals
Latest Hotspot
8 min read
C3 glomerulopathy Indication Strategy Report 2026: C3, Trials and Deals
21 July 2026
C3 glomerulopathy indication strategy report covering epidemiology, C3 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Focal segmental glomerulosclerosis Indication Strategy Report 2026: TRPC5, Trials and Deals
Latest Hotspot
8 min read
Focal segmental glomerulosclerosis Indication Strategy Report 2026: TRPC5, Trials and Deals
21 July 2026
Focal segmental glomerulosclerosis indication strategy report covering epidemiology, TRPC5 biology, active trials, competition and deal signals using PatSnap MCP...
Read →
APOL1-mediated kidney disease Indication Strategy Report 2026: APOL1, Trials and Whitespace
Latest Hotspot
8 min read
APOL1-mediated kidney disease Indication Strategy Report 2026: APOL1, Trials and Whitespace
21 July 2026
APOL1-mediated kidney disease indication strategy report covering epidemiology, APOL1 biology, active trials, competition and deal signals using PatSnap MCP...
Read →
Pulmonary hypertension due to left heart disease Indication Strategy Report 2026: PDE5A, Trials and Deals
Latest Hotspot
8 min read
Pulmonary hypertension due to left heart disease Indication Strategy Report 2026: PDE5A, Trials and Deals
21 July 2026
Pulmonary hypertension due to left heart disease indication strategy report covering epidemiology, PDE5A biology, active trials, competition and deal signals...
Read →
Chronic thromboembolic pulmonary hypertension Indication Strategy Report 2026: GUCY1A1, Trials and Deals
Latest Hotspot
8 min read
Chronic thromboembolic pulmonary hypertension Indication Strategy Report 2026: GUCY1A1, Trials and Deals
21 July 2026
Chronic thromboembolic pulmonary hypertension indication strategy report covering epidemiology, GUCY1A1 biology, active trials, competition and deal signals...
Read →
Mitral regurgitation Indication Strategy Report 2026: TGF-β1, Trials and Deals
Latest Hotspot
8 min read
Mitral regurgitation Indication Strategy Report 2026: TGF-β1, Trials and Deals
21 July 2026
Mitral regurgitation indication strategy report covering epidemiology, TGF-β1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Calcific aortic stenosis Indication Strategy Report 2026: LPA, Trials and Deals
Latest Hotspot
8 min read
Calcific aortic stenosis Indication Strategy Report 2026: LPA, Trials and Deals
21 July 2026
Calcific aortic stenosis indication strategy report covering epidemiology, LPA biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Thoracic aortic aneurysm Indication Strategy Report 2026: TGFBR2, Trials and Whitespace
Latest Hotspot
8 min read
Thoracic aortic aneurysm Indication Strategy Report 2026: TGFBR2, Trials and Whitespace
21 July 2026
Thoracic aortic aneurysm indication strategy report covering epidemiology, TGFBR2 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Abdominal aortic aneurysm Indication Strategy Report 2026: IL-1β, Trials and Deals
Latest Hotspot
8 min read
Abdominal aortic aneurysm Indication Strategy Report 2026: IL-1β, Trials and Deals
21 July 2026
Abdominal aortic aneurysm indication strategy report covering epidemiology, IL-1β biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Peripheral artery disease Indication Strategy Report 2026: PCSK9, Trials and Deals
Latest Hotspot
8 min read
Peripheral artery disease Indication Strategy Report 2026: PCSK9, Trials and Deals
21 July 2026
Peripheral artery disease indication strategy report covering epidemiology, PCSK9 biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →
Acute decompensated heart failure Indication Strategy Report 2026: SGLT2, Trials and Deals
Latest Hotspot
8 min read
Acute decompensated heart failure Indication Strategy Report 2026: SGLT2, Trials and Deals
21 July 2026
Acute decompensated heart failure indication strategy report covering epidemiology, SGLT2 biology, active trials, competition and deal signals using PatSnap MCP...
Read →
Cardiac sarcoidosis Indication Strategy Report 2026: TNF, Trials and Deals
Latest Hotspot
8 min read
Cardiac sarcoidosis Indication Strategy Report 2026: TNF, Trials and Deals
21 July 2026
Cardiac sarcoidosis indication strategy report covering epidemiology, TNF biology, active trials, competition and deal signals using PatSnap MCP evidence.
Read →